Comparative effectiveness of sodium ‐glucose cotransporter‐2 inhibitors among patients with heart failure with preserved ejection fraction

ConclusionsCompared with canagliflozin or dapagliflozin use, empagliflozin use was associated with decreased risk of HF-related and all-cause hospitalizations. Compared with canagliflozin, dapagliflozin was associated with a reduced risk of HF-related and all-cause hospitalizations.

Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 18, 2023 Category: Drugs & Pharmacology Authors: Munaza Riaz, Steven M. Smith, Eric A. Dietrich, David E. Winchester, Jingchuan Guo, Haesuk Park Tags: RESEARCH ARTICLE Source Type: research